Atorvastatin Chemical Properties

Boiling point:

722.2±60.0 °C(Predicted)

Density 

1.23±0.1 g/cm3(Predicted)

pka

4.29±0.10(Predicted)

Atorvastatin Usage And Synthesis

Definition

ChEBI: Atorvastatin is a dihydroxy monocarboxylic acid that is a member of the drug class known as statins, used primarily for lowering blood cholesterol and for preventing cardiovascular diseases. It has a role as an environmental contaminant and a xenobiotic. It is an aromatic amide, a member of monofluorobenzenes, a statin (synthetic), a dihydroxy monocarboxylic acid and a member of pyrroles. It is functionally related to a heptanoic acid. It is a conjugate acid of an atorvastatin(1-).

Clinical Use

Hyperlipidaemia and hypercholesterolaemia

Drug interactions

Potentially hazardous interactions with other drugs Anti-arrhythmics: concentration possibly increased by dronedarone. Antibacterials: azithromycin, erythromycin, clarithromycin or fusidic acid possibly increased risk of myopathy - avoid atorvastatin for at least 7 days after fusidic acid stopped; concentration increased by clarithromycin - do not exceed 20 mg of atorvastatin1 ; avoid with telithromycin; increased risk of myopathy with daptomycin; concentration possibly reduced by rifampicin.
Anticoagulants: may transiently reduce anticoagulant effect of warfarin.
Antifungals: increased risk of myopathy with itraconazole - do not exceed 40 mg of atorvastatin1 ;
increased risk of myopathy with fluconazole, ketoconazole, posaconazole, voriconazole and possibly other imidazoles and triazoles - avoid.
Antivirals: increased risk of myopathy with atazanavir, boceprevir (reduce atorvastatin dose), and possibly darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir or tipranavir (max dose of atorvastatin 10 mg); concentration reduced by efavirenz and possibly etravirine; avoid with dasabuvir, ombitasvir, paritaprevir and telaprevir; possible increased risk of myopathy with ledipasvir - reduce atorvastatin dose; concentration increased by simeprevir - consider reducing atorvastatin dose.
Calcium channel blockers: concentration increased by diltiazem - increased risk of myopathy; concentration of verapamil increased also possible increased risk of myopathy - consider reducing atorvastatin dose.
Ciclosporin: increased risk of myopathy - do not exceed 10 mg of atorvastatin.1 Cobicistat: reduce atorvastatin dose.
Colchicine: possible increased risk of myopathy.
Grapefruit juice: concentration possibly increased.
Lipid lowering agents: increased risk of myopathy
with fibrates, gemfibrozil (avoid) and nicotinic acid.

Metabolism

Atorvastatin undergoes extensive presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Atorvastatin is metabolised by cytochrome P450 3A4 to ortho- and parahydroxylated derivatives and various beta-oxidation products. These products are further metabolised via glucuronidation. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. Atorvastatin is eliminated primarily in bile as active metabolites following hepatic and/or extrahepatic metabolism, but does not appear to undergo significant enterohepatic recirculation.

Atorvastatin(110862-48-1)Related Product Information

• Atorvastatin
• ATORVASTATIN SODIUM
• Diphenyl ether
• Polyvinylpyrrolidone
• Simvastatin
• N-Methyl-2-pyrrolidone
• PHENYL VALERATE
• Povidone iodine
• Phenyl salicylate
• N-Vinyl-2-pyrrolidone
• Propane
• PHENYL RESIN
• Phenylacetic acid
• Atorvastatin calcium
• METHYL-2-PYRROLIDONE
• tert-Butyl (4R,6R)-2-[[[6-(2-4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetate
• P-HYDROXY ATORVASTATIN, DISODIUM SALT
• Heptanoic acid